, /PRNewswire/ -- The global influenza diagnostics market size is estimated to grow by from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of about 7.22% during the forecast period.
Rising incidence of influenza is driving market growth, with a trend towards rising approvals for influenza diagnostic products. However, lack of laboratory infrastructure in developing regions poses a challenge. Key market players include Abbott Laboratories, and Co.
, BICO Group AB, Bio Rad Laboratories Inc., Biocartis NV, bioMerieux SA, Danaher Corp., DiaSorin SpA, F.
Hoffmann La Roche Ltd., Hologic Inc., Princeton BioMeditech Corp.
, QIAGEN NV, Quidelortho Corp., Response Biomedical Corp., SA Scientific Ltd.
, Sd Biosensor Inc., Sekisui Chemical Co. Ltd.
, Siemens Healthineers AG, Tecan Trading AG, and Thermo Fisher Scientific Inc.. Get a detailed analysis on regions, market segments, customer landscape, and companies- The global influenza diagnostics market is experiencing growth due to vendors' focus on creating compliant diagnostic products.
Regulatory bodies like the FDA, EMA, and CFDA have led to an increase in product approvals. Rapid influenza diagnosis is in high demand, leading to a surge in nucleic acid detection technique-based product clearances. Hologic's Panther Fusion SARS-CoV-2/Flu A/B/RSV assay, recently granted FDA clearance, is an example of this trend.
This molecular diagnostic test detects and distinguishes four common respiratory viruses, contrib.
